3D Medicines Inc. (HKG:1244)

3D Medicines Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	149.55	170.24	444.32	666.47	696.74	774.31
Short-Term Investments	147.59	168.29	227.15	120.78	136.68	-
Trading Asset Securities	97.53	99.38	169.52	209.33	108.6	50.18
Cash & Short-Term Investments	394.66	437.91	840.98	996.58	942.03	824.48
Cash Growth	-11.73%	-47.93%	-15.61%	5.79%	14.26%	99.02%
Accounts Receivable	62.13	20.71	47.86	5.46	78.04	65
Other Receivables	-	77.94	75.54	79.54	76.63	7.29
Receivables	62.13	102.44	127.09	85	155.91	72.29
Inventory	4.36	3.51	4.06	4.61	1.2	0.01
Restricted Cash	-	-	-	-	-	0.07
Other Current Assets	87.32	13.37	15.62	8.97	43.93	22.37
Total Current Assets	548.47	557.23	987.75	1,095	1,143	919.23
Property, Plant & Equipment	144.78	137.6	147.73	193.25	177.84	118.54
Long-Term Investments	88.24	87.08	23.34	70.59	-	-
Other Intangible Assets	0.47	0.52	0.63	0.73	0.83	0.93
Other Long-Term Assets	155.76	153.81	56.82	11.89	6.02	17.18
Total Assets	937.72	936.24	1,216	1,429	1,332	1,060

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	69.26	89.18	51.13	71.9	15.88	3.74
Accrued Expenses	-	66.35	166.04	124.35	183.83	111.18
Short-Term Debt	-	120	195.59	174.37	103.99	-
Current Portion of Long-Term Debt	148.94	16.5	9	27	-	3,094
Current Portion of Leases	8.23	9.83	8.27	23.23	11.31	12.75
Current Income Taxes Payable	-	-	0.06	1.91	-	1.43
Current Unearned Revenue	4	-	-	24.54	-	-
Other Current Liabilities	222.59	83.05	57.69	53.08	61.24	24.98
Total Current Liabilities	453.02	384.92	487.79	500.37	376.25	3,248
Long-Term Debt	-	-	16.5	29.24	27	38.82
Long-Term Leases	14.22	6.45	8.25	28.58	33.4	45.99
Total Liabilities	467.24	391.37	512.54	558.2	436.65	3,333

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.23	0.23	0.23	0.23	0.22	0.06
Additional Paid-In Capital	-	4,798	4,785	4,785	4,228	134.66
Retained Earnings	-	-4,521	-4,343	-4,161	-3,636	-2,612
Treasury Stock	-0.01	-0.01	-0.17	-0.01	-0.03	-0.03
Comprehensive Income & Other	524.77	319.23	343.22	311.97	350.98	239.02
Total Common Equity	524.99	596.73	785.06	936.74	943	-2,238
Minority Interest	-54.51	-51.85	-81.35	-66.05	-47.59	-34.55
Shareholders' Equity	470.48	544.87	703.71	870.69	895.41	-2,273
Total Liabilities & Equity	937.72	936.24	1,216	1,429	1,332	1,060

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	171.39	152.78	237.62	282.43	175.7	3,192
Net Cash (Debt)	223.28	285.13	603.36	714.15	766.33	-2,367
Net Cash Growth	-21.42%	-52.74%	-15.51%	-6.81%	-	-
Net Cash Per Share	0.91	1.16	2.46	3.13	16.85	-60.61
Filing Date Shares Outstanding	245.92	245.92	244.97	245.07	224.2	36.45
Total Common Shares Outstanding	245.92	245.92	244.97	245.07	224.2	36.45
Working Capital	95.45	172.31	499.96	594.78	766.81	-2,329
Book Value Per Share	2.13	2.43	3.20	3.82	4.21	-61.40
Tangible Book Value	524.51	596.2	784.44	936.01	942.17	-2,239
Tangible Book Value Per Share	2.13	2.42	3.20	3.82	4.20	-61.43
Machinery	-	9.6	9.58	8.28	8.06	7.06
Construction In Progress	-	112.02	112.02	112.02	99.87	28.16
Leasehold Improvements	-	31.16	31.16	35.09	33.16	23.43

Data Source: S&P Global Market Intelligence Last updated: Aug 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 20, 2026

Data Sources Report a data error